At a glance
- Originator AstraZeneca
- Class Anti-inflammatories
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 16 Jun 1997 Preclinical development for Inflammation (Unknown route)